Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant

Abolaji S Olagunju, Andrew V D Sardinha, Gustavo P Amarante-Mendes

Abstract read

In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abolaji S OlagunjuDepartamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, SP, Brazil.

Andrew V D SardinhaDepartamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, SP, Brazil.

Gustavo P Amarante-MendesDepartamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-7851-6205

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/25395-1; 2021/13486-5National Council for Scientific and Technological Development 308927/2019-2; 311122/2023-0; INCTiii 46543412014-2

6 · The paper itself

Abstract

One of the main objectives of developing new anti-cancer vaccine strategies is to effectively induce CD8+ T cell-mediated anti-tumor immunity. Live recombinant vectors, notably

Indexed as

Cancer VaccinesCD8-Positive T-LymphocytesListeria monocytogenesMice, Inbred C57BLMice, KnockoutNecroptosisOvalbuminPhosphate-Binding ProteinsPyroptosisAnimalsCaspase 1Caspases, InitiatorCell Line, TumorGasderminsIntracellular Signaling Peptides and ProteinsMelanoma, ExperimentalCancer VaccinesCasp1 protein, mouseCasp4 protein, mouseCaspase 1Caspases, InitiatorGasderminsGsdmd protein, mouseIntracellular Signaling Peptides and ProteinsMLKL protein, mouseOvalbuminPhosphate-Binding ProteinsProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouseVaccines, Syntheticanti-tumor vaccineCD8 T cellL. monocytogenesnecroptosispyroptosis

Identifiers

PMID39452700

DOI10.3390/pathogens13100828

PMCPMC11510422

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.